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Abstract 
 
Opioid abuse is one of the greatest health problems around the world. There have been recent 
increases in worldwide use of heroin, particularly in the USA and Western and Central Europe.  
Heroin abuse leads to the deaths of around 150,000 people per year around the world. Once 
heroin is absorbed into the body it is rapidly metabolised to the pharmacologically active 6-
monoacetylmorphine (6-MAM). 6-MAM is then metabolised to morphine.  The final major 
steps of metabolism are the formation of the pharmacologically inactive morphine-3-
glucuronide (M3G) and the pharmacologically active morphine-6-glucuronide (M6G). In 
previous studies examining heroin/morphine related deaths the concentrations of free morphine 
and total morphine have been used for data interpretation. Due to the introduction of liquid 
chromatography mass spectrometry (LC-MS) it is now becoming more common to consider 
the presence of free morphine and its metabolites morphine-3-glucuronide and morphine-6-
glucuronide in post mortem case interpretation. However, the amount of quantitative data of 
morphine and its metabolites in post-mortem cases is still not exhaustive and little is known 
about postmortem tissues distribution and concentration for heroin related deaths. To fulfill the 
lack of information and help colleagues in data interpretation we report the concentration of 
morphine, morphine-3-glucuronide, morphine-6-glucuronide and qualitative results for 6-
MAM, noscapine, papaverine and codeine in 44 cases in a series of commonly sampled 
postmortem matrices (femoral blood, cardiac blood, brain (thalamus), liver (deep right lobe), 
bone marrow (sternum), muscle (psoas) and (vitreous) using a validated LC-MS/MS method.   
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1. Introduction 
Heroin (diacetylmorphine or diamorphine (BAN)) is an opioid analgesic that is abused by 
around 16.5 million people worldwide and in 2015 was responsible for an estimated 150,000 
deaths 1. The use of heroin is however changing around the world. Europe is currently seeing 
a recent increase in deaths after seeing a long term decline in the use of heroin 2, this increase 
in abuse is also being seen in other parts of the world such as South West and Central Asia 1. 
North America in particular has seen a large 145% increase in heroin users since 2007 1. 
Although there has been a recent increase in the use and abuse of synthetic opioids worldwide 
2 the abuse of heroin is still a global problem to be addressed. Heroin is commonly abused by 
various routes the most common ones being intravenously, orally and inhalation (smoking) 3. 
Heroin, once absorbed, is rapidly deacetylated and pharmacologically activated by metabolism 
with the formation of 6-monoacetylmorphine (6-MAM) with a half-life of about 2-5 minutes 
4.  6-MAM is then hydrolysed rapidly to morphine (t½ ~15 min). The major final steps of the 
metabolism of morphine are the conjugation of morphine to form the pharmacologically 
inactive morphine-3-glucuronide (M3G) and the pharmacologically active morphine-6-
glucuronide (M6G). N-demethylation of morphine also results in the formation of the inactive 
minor metabolite normorphine 5. Due to various factors it is difficult to interpret postmortem 
morphine concentrations. These factors include overlapping concentrations of morphine 
measured in deceased and living patients6, the rapid development of tolerance to opiates in 
users 6 and the possibility of changes in the blood concentration of opiates after death 7. Due to 
the routine introduction of LC-MS/MS into laboratories it is becoming more common to 
quantitate the concentrations of morphine, morphine-3-glucuronide and morphine-6-
glucuronide in post mortem samples 8, 9 rather than to determine the concentration of free 
morphine and total morphine levels (free + conjugated morphine levels) to determine possible 
toxicity 10. To fulfill the lack of information and help colleagues in data interpretation we report 
the concentration of morphine, morphine-3-glucuronide and morphine-6-glucuronide whilst 
also showing qualitative results for noscapine, papaverine and codeine in 44 cases in a series 
of commonly sampled postmortem matrices (femoral blood, cardiac blood, brain (thalamus), 
liver (deep right lobe), bone marrow (sternum), muscle (psoas) and (vitreous) using a validated 
LC-MS/MS method.  
  
2. Material and Methods 
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2.1 Sample collection 
 
All samples were collected and analysed as part of the routine autopsy procedure for suspected 
heroin deaths (2010-2012). These samples included femoral venous blood (unpreserved sample 
and preserved sample with potassium fluoride/sodium oxalate), unpreserved cardiac blood, 
muscle (psoas), bone marrow (sternum), liver, brain (thalamus) and preserved vitreous humour. 
Sample collection was performed according to the following protocol:  
 
All fluid samples (blood, vitreous) were collected using a 12 gauge needle and syringe. 
Unpreserved fluid samples were stored in a 20 ml Sterlin® tube. Preserved samples were stored 
in a 2.5% w/v sodium fluoride/potassium oxalate tube. Femoral venous blood was collected by 
the superior clamping of the femoral vein before sampling. Cardiac blood was sampled for 
either of the ventricles. Vitreous humour was sampled from both eyes and mixed. For all tissue 
samples the area was wiped clean before sampling commenced, samples were stored in 20 ml 
Sterlin® tubes. For psoas muscle sampling an incision was then made anteriorly to remove 
approximately 1cm3 of interior tissue to minimise external contamination. For liver an incision 
was made across the middle right lobe to provide a 1cm3 of centrally located tissue to avoid 
external contamination. For bone marrow the sternum was cut laterally between the 1st and 2nd 
rib to allow access to the bone marrow.  Tweezers were used to collect between 0.5 - 1 g of 
bone marrow from the sternum cavity. For the brain approximately 1 cm3 of the thalamus was 
wiped clean then collected. Samples were stored at 4ºC for 1 week and then stored at -20 ºC 
until analysis. All analysis was completed with 5 weeks of the samples being collected.  
 
 
 
 
 
 
2.3 Standard Solutions, Calibration Curve and Quality Control  
  
Morphine (1mg/ml), morphine-3β-D-glucuronide (M3G) (1mg/ml) and morphine-6-β-D-
glucuronide (M6G) (100µg/ml) methanolic standards (LGC Standards, Teddington UK) were 
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used to prepare a fresh 25 mg/L combined standard solution then diluted with blank equine 
plasma (TCS Biosciences, Buckingham, UK) to prepare a 7 point calibration curve (0.01, 
0.025, 0.05, 0.1, 0.25, 0.5 and 1 mg/L). Separate quality control (QC) standards were prepared 
in blank equine plasma at a concentration of 0.025 and 0.5 mg/L. Morphine-3β-D-glucuronide-
D3 (M3Gd3) and morphine-D3 (Md3) both 1 mg/ml methanolic solutions (LGC Standards, 
Teddington UK) were diluted in water at the final concentration of 1mg/L and used as Internal 
Standards. HPLC grade acetonitrile, ammonium carbonate, ammonium formate, formic acid 
and HPLC grade methanol were supplied by Fisher Scientific (Loughborough UK).   
 
2.3 Sample Preparation and extraction 
 
2.3.1 Tissue Sample Preparation 
For extraction, liver, brain, bone marrow and muscle were homogenised, adapting and applying 
a previous published procedure11. In summary tissues were dried using tissue paper, accurately 
weighted and homogenised (Janke & Kunkel Ultra-Turrax T25) with 4 parts of water. 
Thalamus and bone marrow were accurately weighted and homogenised with 2 parts of 
methanol and 6 parts of hexane. The methanol/hexane homogenates were then centrifuged and 
the top hexane layer discarded.  
 
2.3.2 Sample Extraction 
The sample extraction was based on a previously published method10. Following 
homogenisation 200 µl of liver was diluted with 1000 µl equine plasma. For all the other 
biological samples, quality controls and calibrators, 150 µl of sample was diluted with 150 µl 
equine plasma.  900 µl of liver sample and 300 µl of all the other biological samples were 
spiked with 50 µl of Md3 and 50 l of M3Gd3 (IS). After vortexing, 1ml of 0.5M Ammonium 
Carbonate solution was added to each sample, now ready to be extracted. Solid phase extraction 
was performed using a Varian Bond Elut LRC-C18, 200mg cartridges. The cartridges were 
conditioned using 2ml of methanol followed by 2ml of water and finally 1ml of 0.5M 
ammonium carbonate solution. Then, 1ml of the sample was loaded onto the cartridge and 
allowed to drain to the clear tube. The cartridges were washed using 5ml of 0.005M ammonium 
carbonate solution the washing solution discarded and the cartridges dried for 5 minutes. 1ml 
of 70:30 ACN:H2O solution was loaded onto the cartridges and allowed to elute into a clean 
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glass vial. The eluents were evaporated to dryness under air at 45°C. The evaporated eluent 
was reconstituted with 100 µl of freshly made LC-MS mobile phase (96% phase A: 4% phase 
B), transferred into a HPLC vial for analysis. 
 
2.4 Sample Analysis  
A 1200 Agilent HPLC system interfaced with an Applied Biosystem 3200 Q TRAP triple-
quadrupole linear ion trap mass spectrometer (AB Applied Biosystem, Foster City,  CA, USA) 
equipped with an electrospray ionization source (ESI) was used to analyse all the samples. Data 
acquisition was achieved with Analyst 1.5 software.  Separation of all analytes was 
accomplished using a Phenomenex Synergi 4µ Polar-RP 80A Column (150 mm × 2 mm × 
4µm) protected by a Phenomenex Security Guard column (Macclesfield, UK). Mobile Phase 
A consisted of a 1mM ammonium formate and 0.1% formic acid solution (around pH 2.7). 
Mobile Phase B was a 50% acetonitrile solution with 1mM ammonium formate and 0.1% 
formic acid (around pH 3.8).   
The qualitative and quantitative screening were based on a previously published method 10. For 
the qualitative screening a gradient method was applied. Following injection the eluent was at 
1.5% ACN (97% A, 3%B) for the first 3 min, ramping to 47.5% ACN over 5 min (5% A, 
95%B) and held for 3.5 min. The eluent was then reduced back to the initial 1.5% ACN over 
0.5 minutes and was held for a further 3 minutes. This gave a total run time of 15 minutes. 
Flow rate was 0.6 ml/min, injection time was 20 seconds and column temperature was set at 
40 °C. The injection volume was 20l. The following ion transitions and retention times were 
observed: Morphine (m/z 286/286, 286/201, 286/165), morphine-3-glucuronide (m/z 462/462, 
486/286, 462/268), morphine-6-glucuronide (m/z 462/462, 486/286, 462/268), 6-
monoacetylmorphine (6-MAM) (m/z 328/328, 328/193, 328/165), noscapine (m/z 414/414, 
414/220), papaverine (m/z 340/340, 340/202), codeine (m/z 300/300, 300/215, 300/165). 
Internal standards: Morphine-d3 (m/z 289/289, 289/201, 289/165), morphine-3-glucuronide-d3 
(m/z 465/465, 485/289, 465/204).  
Free morphine, M3G and M6G quantitation was achieved with an isocratic method of 1.5% 
acetonitrile (97% A, 3%B). The triple-quadrupole linear ion trap mass spectrometer performed 
the scan in positive mode using ion spray ionization (voltage 5500 V). The ion source 
temperature was set at 700 °C, DP 20 V, EP 10 V.  
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2.5 Method Validation 
 
The method was validated according to the guidelines of Peters et al. 12, with the matrix effects 
being evaluated by the methods of Matuszewski et al. 13. The morphine, morphine-3-
glucuronide and morphine-6-glucuronide linearity (r2 >0.99) was achieved applying a linear 
regression with a 1/x weighting factor on a seven points calibration curve (0.01 mg/L, 0.025 
mg/L, 0.05 mg/L, 0.1 mg/L, 0.25 mg/L, 0.5 mg/L and 1 mg/L). A series of quality control 
samples in plasma at concentration of 0.025 mg/L and 0.5 mg/L for morphine and morphine 
glucuronides were prepared and analysed on different days to determine the precision (CV%) 
and accuracy (bias) of the method. Accuracy and bias (both interday (n=5) and intraday (n=30) 
were within the acceptable ranges (±15%) proposed by Peters et al. 12. The MRM transitions 
selected for quantitation were the following: for morphine 286/165 (against Morphine-d3 
289/152), for Mophine-3-and-6-glucuronide 462/286 (both against Morphine-3-glucuronide-
d3 465/289). Lower limit of quantification and (LLOQ) and limit of detection (LOD) were 
determined as the minimum concentration that would produce a signal-to-noise ratio of ten and 
three respectively. The LOD for morphine, morphine-3-glucuronide and morphine-6-
glucuronide were 0.004 mg/L, 0.003 mg/L and 0.004 mg/L respectively, with the LLOQ being 
0.01 mg/L for all compounds. Evaluation of the results obtained for morphine, morphine-3-
glucuronide and morphine-6-glucuronide in all biological matrices analysed indicated that it 
was possible to use the calibration curve in plasma for quantitation since all spiked tissue 
concentrations were all within 20% of the expected concentration.  
 
To investigate matrix effects; morphine, morphine-3-glucuronide and morphine-6-glucuronide 
were spiked (along with IS) at different concentrations (0.025 mg/L and 0.5 mg/L) in at least 
5 different samples of SAGM blood (Transfusion Unit. Ninewells Hospital, Dundee, UK), 
porcine vitreous, homogenised porcine/bovine bone marrow, bovine  muscle, porcine brain and 
porcine/bovine liver (all local butcher); extracted, analysed and measured against the plasma 
calibration curve to determine the deviation from the true value.  Evaluation of the results 
obtained for morphine, morphine-3-glucuronide and morphine-6-glucuronide in all biological 
matrices analysed indicated that it was possible to use the calibration curve in plasma for 
quantitation since all spiked tissue concentrations were all within 20% of the expected 
concentration. The concentrations of the solid matrices were calculated according to the 
method of Flanagan et al. 11. The validation results are shown in table 1. 
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2.6 Statistical Analysis 
 
Morphine results obtained from all biological matrices underwent statistical Pearson 
Correlation analysis to determine whether any linear relation exist between different samples. 
The data was also analysed using “Principal Component Analysis” (PCA).  
PCA is an unsupervised multivariate procedure and is a well-known linear data compression 
and feature extraction technique 14. It derives new, uncorrelated variables that are linear 
combinations of the original variable set ordered by reducing variability. PCA is mainly used 
to reduce the dimensionality of a data set while retaining as much information as possible by 
eliminating the lowest-ranking variables. It is a simple and fast method but remains a linear 
approach, so any nonlinear correlation between variables will not be retained. The scores 
produced may be plotted in two or three dimensions to inspect the data. Therefore it might be 
possible to relate the data using statistical methods such as principal component analysis 
(PCA). 
 
3. Results and Discussion 
 
A total of 44 cases of death from heroin use were investigated. The presence of 6-
monoacetylmorphine (6-MAM) in at least one of the case samples and the case circumstances 
were used as confirmation of illicit rather than medicinal heroin use. Each sample collected at 
autopsy (cardiac blood, femoral blood, preserved (fluoride/oxalate) femoral blood, preserved 
vitreous, liver, bone marrow, psoas muscle and brain) underwent initial qualitative screening 
for morphine, morphine-3-glucuronide, morphine-6-glucuronide, codeine, 6-MAM, 
papaverine and noscapine). Following the quantitative screen the levels of free morphine, 
morphine-3-glucuronide and morphine-6-glucuronide were determined in all samples.   
 
3.3 Age and gender of heroin users 
 
Of the 44 cases of death following heroin use 79.5% were male with a mean age of 36 years; 
(median 35 years; range 21 to 65 years). 20.5% were female with a mean age of 34 years, 
(median 33 years; range 21 to 46 years). The mean and median age for all cases (regardless of 
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sex) was 35 years. Averages for age and gender were similar to previous other studies of heroin 
related fatalities 6, 15 
 
3.1 Qualitative Screening 
In the case of decomposition the full range of toxicological samples may not be available for 
testing. In order to determine the samples in which morphine, morphine-3-glucuronide and 
morphine-6-glucuronide can be detected we carried out qualitative screening of blood (femoral 
and cardiac), vitreous, liver, brain (thalamus), muscle (psoas) and bone marrow.  The results 
of the qualitative screening are found in Table 2. The presence of morphine was confirmed in 
all cases for cardiac blood, unpreserved femoral blood, preserved femoral blood and vitreous 
with high levels of detection of morphine and in brain, liver, bone marrow and muscle samples 
(98%, 95%, 91% and 86% detection) respectively. Similar to the study by Thaulow et al 16, 
morphine-3-glucuronide was detected in all case samples for cardiac blood and unpreserved 
femoral blood. High levels of detection were observed in all other matrices; preserved femoral 
blood (98%), brain (84%), liver (98%) bone marrow (75%) samples, vitreous (95%) and 
muscle (84%) samples. Previous work 16 has only determined detection of M3G in vitreous 
(88%) and muscle (89%) which are similar to our data.  Thaulow et al. 16 in agreement with 
our data detected morphine-6-glucuronide in fewer matrices than morphine and morphine-3-
glucuronide, in our data M6G exhibited with high rates of detection >86% in all samples apart 
from muscle (50%) bone marrow (41%) and thalamus (43%). This would be expected as more 
M3G is produced by metabolism of morphine than M6G 17. However we detected M6G in 
psoas in a higher number of cases (50% vs 9%) and also in vitreous humour (84% vs 44%) 
than the Thaulow et al. study 16.  These results suggest that the best matrices for the 
confirmation of free morphine and its glucuronide metabolites are blood (femoral and cardiac) 
> liver > vitreous. In muscle, bone marrow and brain, morphine will be detected in most cases 
but not all of the time. This may mean that in decomposed bodies the use of morphine may not 
be able to be confirmed even if the deceased had taken morphine. The presence of morphine 
and its main metabolites morphine-3-glucuronide and morphine-6-glucuronide have previously 
been reported in a number of human cases for various matrices and give similar results to those 
that we found in this study with morphine-3-glucuronide and morphine-6-glucuronide 
detectable in blood, vitreous, brain, liver, lung and kidney 18-24.  
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The presence of morphine alone does not confirm the use of heroin as morphine can be 
produced as a metabolite of codeine and morphine can be abused by itself. In order to 
definitively identify the use of heroin, 6-MAM needs to be detected. However 6-MAM is 
unstable in the body being metabolised even after death by cholinesterases. With particularly 
high concentrations of esterases found in liver, heart, lung, kidney and blood 25. Our study 
shows that as with other studies 24, 26, 27 vitreous is the best sample for the detection of 6-MAM 
being detected in 100 % of cases. In blood the 6-MAM was most stable in fluoride/oxalate 
preserved samples where it was detected in 61% of samples. In all other matrices 6-MAM was 
detected in <52% of case the worst samples for the detection of 6-MAM was liver and bone 
marrow (2% and 5% respectively). However it is unclear why so little 6-MAM was detected 
in bone marrow as in previous human and animal studies 6-MAM has been shown to be 
detectable 2 months after death 23, 28. This may be due to the different sampling sites used 
between this study (sternum) and the previous studies (both femur) or a lack of time for 6-
MAM to equilibrate with the bone marrow compartments before death occurred.  
 
Another important piece of information that can be obtained from toxicological screening is 
the determination of the use of heroin which can come from either illicit or medicinal 
(diamorphine) sources. The illicit heroin contaminants which occur in the largest amounts due 
to the processing of the opium poppy are noscapine, papaverine, codeine, 6-acetylcodeine, 
thebaine, and narceine 29. The most commonly used biomarkers for illicit heroin are noscapine 
and papaverine as they are found in the opium poppy and have been found to survive the 
common two methods of heroin production, the lime method (South East Asia) and the 
ammonia method (West Asia) 30. The amount of noscapine and papaverine has been found to 
vary based on the batches of heroin. In 513 illicit seizures of heroin from the Netherlands 
between 1994-1999 noscapine was detected in 15% and papaverine detected in 1.3% (median 
values) 29. In 85 Iranian heroin samples (2008-2009) Akhgari et al 31 reported that 43.5% of 
samples contained noscapine and 42.4% papaverine. From another study carried out by O’Neil 
et al 32 only 5% of samples of Southeast Asian Origin contained papaverine and noscapine, 
where none of the illicit heroin of Indian origin had either papaverine or noscapine.  
It was also reported that 59% of illicit heroin of Pakistani origin contained noscapine and 
papaverine, whereas 88.4 % and 88.1 % of Iranian and Turkish origin respectively contained 
noscapine and papaverine. Illicit heroin samples have also been found not to contain noscapine 
and papaverine 29-32 so with these studies showing that varying concentrations of noscapine and 
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papaverine can be found in illicit heroin samples and as both noscapine and papaverine can be 
found in over the counter drugs and foods containing poppy seeds. The centrally acting cough 
suppressant noscapine is commonly prescribed in Asia and several European countries and 
papaverine is available for the treatment of erectile dysfunction and as an analgesic as a 
component of papaveretum which contains morphine, papaverine and codeine 33. Several 
studies show that noscapine and papaverine are not present in illicit heroin samples and 
therefore negative results do not infer that illicit heroin was used. Use of illicit heroin attributed 
due to the presence of noscapine and papaverine should be done after excluding their 
provenance from other prescribed drugs and from patient given atracurium. 
 
Overall for all compounds investigated we found a slightly higher percentage of positive cases 
for preserved matrices (blood and vitreous) showing that more information can be gained from 
preserved blood samples compared to unpreserved blood samples. 
 
3.2 Quantitative results: 
 
Interpretation of the postmortem results requires investigation (case history), pathology and 
also laboratory analysis that are evaluated in the context of each other 34. In order for laboratory 
investigations to be placed into correct context data must be obtained from case studies of 
heroin death. To the best of the authors’ knowledge this is the first publication that has complete 
case studies for heroin deaths in a variety of matrices with both free morphine and its 
glucuronides. We determined the concentrations of free morphine, morphine-3-glucuronide 
and morphine-6-glucuronide in a variety of matrices as shown in Table 3. An overall summary 
of the results are given in table 4. The general consensus is that ‘gold standard’ sample for 
interpretation in postmortem toxicology is that of femoral blood which is thought to be affected 
the least by the “toxicological nightmare” of postmortem drug redistribution 7.  The free 
morphine levels in unpreserved femoral blood (median 0.21 mg/L, range 0.01-1.35mg/L, n=44) 
were not found to be significantly higher than that found in preserved femoral blood (median 
0.14 mg/ L, range 0.01-1.19 mg/L, n=44). As can be seen in table 5 the mean values of free 
morphine are similar to a variety of other studies that reported free morphine levels in femoral 
blood. These results overlap with the free morphine blood levels reported in apprehended 
drivers in Sweden median 0.15 mg/L range 0.02-1.13mg/L. n=124 6 and so confirm other 
reports that the confirmation of death due to morphine must be confirmed from as much case 
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information as possible rather than looking at drug reference ranges 35.  The morphine results 
that have typically been used in the past to determine the role of morphine in opiate deaths has 
been that of free morphine (unmetabolised morphine) and total morphine (unmetabolised 
morphine and metabolised morphine). However this does not allow investigation of the 
individual roles of the glucuronide metabolites in opiate toxicity. Due to the lack of previous 
studies, especially in non-blood matrices studies we also investigated the levels of morphine-
3-glucuronide and morphine-6-glucuronide. The results are shown in table 2 and 3 as shown in 
table 5 these results are similar to the ranges that have been reported in previous studies that 
measured femoral blood. It has been suggested that the molar ratio of M3G:M6G might be 
responsible for the analgesic effect (and thus toxic effects of morphine) 36 however this is based 
on the assumption that M3G antagonises the analgesic (and also respiratory depressant) effects 
of M and M6G. This effect has been demonstrated in vivo following intracerebroventricular 
injections 37, 38 but has not been repeated in either animal studies 39, 40 or human studies in the 
more physiologically relevant intravenous injection 41. So the M3G:M6G ratio is unlikely to 
indicate the effects of morphine as previously suggested. Its relevance has also been called into 
question as we would have to assume that no detectable levels of both M3G and M6G were 
present before the administration of heroin, something that may not be true in chronic 
heroin/morphine users. It has also been found that the metabolites are not produced in equal 
amounts and that the amounts of glucuronide metabolites can depend on the route of 
administration 17.  
 
Morphine-6-glucuronide has been shown in numerous studies to have a similar or greater 
analgesic potency than morphine 41-43, like morphine it is also thought to give a similar level of 
reward as morphine 44-46 but appears to have less of a respiratory depressant effect than 
morphine in human studies 47 possibly due having less affinity for the 2 opiate receptor than 
morphine. The 2 opiate receptor is thought to be responsible for the side effects of opiate 
drugs. Both morphine and M6G have similar affinities for the 1 receptor 48, 49.  
 
In all cases the concentrations of free morphine, morphine-3-glucuronide and morphine-6-
glucuronide were higher in cardiac blood than femoral blood. This was as expected as in 
previous studies that investigated both cardiac and femoral blood the cardiac blood was 
generally found to be higher than the femoral blood 50-52. Two studies have shown 
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concentrations of free morphine that have been higher in femoral blood than cardiac blood. In 
one case the cardiac morphine concentration was 0.8mg/L (left ventricle), 0.46mg/L (right 
ventricle) with a femoral blood of 1.35mg/L 20. In a study performed on 4 cases of heroin 
related deaths Skopp analysed the concentration of morphine, M3G and M6G sampling the 
blood from different sites: aorta, infra- and suprarenal potion of inferior vena cava, the superior 
vena cava, the femoral and subclavian vein, right and left ventricles 53. Case number one 
showed concentration of cardiac blood (left and right ventricle) for all three compounds higher 
than the one in femoral blood (left and right femoral vein). For the second case morphine 
concentration in the blood from the right ventricle was lower than the blood in the right femoral 
vein. In the same case M6G was overall higher in cardiac blood than femoral blood. M3G was 
not quantifiable in cardiac blood due to biological matrix interferences. The third case 
morphine in left femoral blood was lower than the left ventricle but higher than the right 
ventricle, and also M6G presented a higher concentration in the blood from the left femoral 
vein than the blood of the left ventricle. Case four had a lower concentration for M3G and M6G 
in the blood from the left ventricle than the right and left femoral vein.  
 
Liver was historically a common tissue for toxicological analysis due to its large mass. We also 
investigated the free morphine & morphine glucuronide metabolites in the right lobe of the 
liver a part of the liver that is thought to be the least effected by postmortem redistribution, 
especially from the stomach 7. Concentrations of free morphine in liver showed a mean 
concentration of 0.62mg/kg with a range of 0-2.55mg/kg, M3G was 0.7mg/kg (range 0-4.68), 
M6G was 0.29mg/kg (range 0-1.76). We are the first study to show free morphine and the 
glucuronide metabolites of morphine in liver samples. Only Klingman reported in study of one 
case (intoxication following morphine, tramadol and atracurium intake) the concentration of 
morphine as well M3G and M6G in liver which were 2.32, 14.94 and 15.1 mg/kg respectively 
55.  Three other studies investigated free morphine concentrations alone. Wyman analysed 25 
heroin deaths. Morphine concentration in liver averaged 0.04-1.56 mg/kg (mean 0.33 mg/g) so 
slightly lower than our results 18. Moriya described just one case with a morphine concentration 
of 1.44 mg/kg 20. Felby investigated morphine concentration in the liver of 14 heroin deaths. 
The range reported was 0.4-18 mg/kg, average 2.57mg/kg 21.  In our study liver was the 
biological matrix showing the highest mean concentration of morphine (0.62 mg/kg). In the 
other studies investigating liver they also found liver to contain the highest concentration of 
morphine of all the matrices tested 18, 20, 21, 54. The high concentrations of morphine and 
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metabolites in the liver may mean that the liver is a possible depot for postmortem 
redistribution.  
 
Muscle is commonly used for detection of morphine use rather than for interpretive purposes 
55. However it has been suggested that muscle may give a reasonable estimate of the 
concentration of a drug in the body at the time of death 56. We quantitated free morphine, M3G 
and M6G in the psoas muscle. Results given as mean and range. Morphine 0.19mg/kg, 0-
1.13mg/kg; M3G 0.09mg/kg, 0-0.91mg/kg; M6G 0.03mg/kg, 0-0.15mg/kg. As with the studies 
in the liver previous studies have only investigated free morphine concentrations in the muscle 
and didn’t investigate M3G and M6G. The other studies, muscle was either from a different 
site (thigh) or was not given which as drug concentrations have been shown to differ in the 
muscle depending on the site of sampling 57 the results may not be directly comparable to the 
current study. With Moriya, 1 case of heroin death was considered. Right femoral muscle had 
a morphine concentration of 0.74 mg/kg 20. Felby reported the results of morphine 
concentration analysed in 14 cases of victims due to heroin intake 21. Muscle morphine 
concentration averaged 0.39 mg/kg (range 0-2 mg/kg). Morphine concentration in muscle was 
1.13 mg/kg in Klingmann study 54. All of these study demonstrated larger concentrations of 
morphine compared to the data presented here.  
 
Bone marrow has been suggested as a possible source of information about morphine in 
decomposed bodies due to bone marrow being protected from the environment in 
decomposition situations 23. We found that the mean concentration of free morphine in bone 
marrow was 0.25 mg/kg range 0-3.23 mg/kg. This was similar to the bone marrow morphine 
level found in a heroin addict immediately after death (0.2 mg/kg). It is unclear if the 
concentrations of morphine vary depending on the bone marrow sampling site.  
 
The brain is an important site of action for the respiratory depressant effects of morphine, the 
effect that is thought to cause death in heroin fatalities 58. We investigated the concentration of 
free morphine in the thalamus. The mean concentration of free morphine was 0.26 mg/kg 
(range 0-1.96 mg/kg); M3G 0.06mg/kg, 0-1.12 mg/kg; M6G 0.01 mg/kg. Previous studies have 
looked at the concentrations of morphine in the brain, but as with other tissues there is no 
standard sampling site. One study looked at two regions in the brain medulla (mean 0.24 mg/kg 
range 0.05-0.45mg/kg) and cerebellum (mean 0.34 mg/kg, range 0.05-0.67mg/kg) 59. These 
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results were similar to those that we obtained but may indicate that the concentration of 
morphine is not uniform thorough out the brain and for future comparison of cases specific 
sampling sites should be identified. Other cases where the brain was analysed also gave similar 
concentrations as found in our study. Moriya 20 presented the results of a subject who died after 
injecting heroin and methamphetamine. Cerebrum was analysed morphine concentration was 
0.34 mg/kg. In another study 22 Pare analysed morphine concentration in the thalamus 0.24 
mg/kg (range 0-0.67 mg/kg). Only one study investigated the concentration of morphine as 
well as its metabolites in and unidentified area the brain. Klingmann found the concentration 
of morphine was 0.52 mg/kg, M3G 1.42 mg/kg and M6G 1.24 mg/kg 54. 
As discussed above vitreous is commonly used to confirm the use of heroin, via the detection 
of 6-MAM when morphine is detected due to the stability of 6-MAM in vitreous but is not 
commonly used for the quantitation of morphine levels. The median concentration of 
morphine, M3G and M6G in this study for vitreous were 0.08mg/L (range 0.01-0.49 mg/L); 
0.10 mg/L (range 0.01-0.65 mg/L) and 0.02 mg/L (0.01-0.19 mg/L) respectively. The morphine 
concentration here reported was the lowest among all the matrices analysed. Other studies that 
quantitated morphine and its metabolites in vitreous have reported concentrations of morphine 
and its glucuronides with similar levels than us. Morphine median 0.05mg/L (range 0.006-
0.195 mg/L); M3G median 0.16 mg/L (range 0.036-0.250 mg/L) and M6G median 0.02 mg/L 
(0.003-0.046 mg/L) 19 Morphine median 0.06mg/L (range 0.011-0.46 mg/L); M3G median 
0.12 mg/L (range 0.016-2.0 mg/L) and M6G median 0.051 mg/L (0.014-0.31 mg/L) 16 and 
showing that quantitation of morphine and its metabolites can be achieved.  
3.3 Relationships between and femoral blood and the other various matrices 
With the various states that bodies can be found in due to the manner of death or subsequent 
decomposition femoral blood may not be available. In the past it has been suggested that other 
biological samples may be used to predict the femoral blood sample for subsequent analysis 60. 
For this reason we investigated the correlation of femoral blood with the various matrices.  For 
free morphine cardiac blood (R2 = 0.79), bone marrow (R2 = 0.70), muscle (R2 = 0.69) and 
brain (R2 = 0.73) significant correlations were observed, which were not seen with liver (R2 = 
0.49) and vitreous (R2 = 0.44). These results in vitreous when compared to femoral blood are 
in agreement with a previous study (R2 =  0.26; n=40 61, as are the results of femoral blood to 
cardiac blood (R2 = 0.76) and psoas muscle (R2 = 0.75) 16  but don’t agree with the results of 
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two other studies that showed significant correlations between femoral blood and vitreous 
concentrations (R2 = 0.87; p<0.01, n=69 62),  (R2 = 0.72; p<0.001, n=52 60) and (R2 = 0.79; 
p>0.001, n=45 16). The differing sets of results obtained by the various groups and this study 
show that although correlations may exist for populations due to differences such as individual 
tolerance, individual metabolism, survival time after the administration of the drug and also 
postmortem redistribution 63, 64 that in the absence of a femoral blood sample in a case other 
samples should not be used to attempt to determine the femoral blood concentration.  
Due to the complex nature of the data collected the visualisation techniques PCA was applied 
to the data, below in Fig 1 it is shown the 3D scatterplot of morphine results. The figure shows 
the PCA scores from the Morphine levels in different matrices represented by the first three 
PCs. PC1 contains 78.7 % while PC2 contains 8.1% and PC3 contains 5 % of the total variance. 
All matrices from different sites form three groups or classes in the plot: blood, bone marrow 
and brain at the bottom; muscle and liver at the top, vitreous by itself at the centre. The plot 
shows that most biological samples are visually separable when the first three PCs are utilised, 
with cardiac blood and brain showing highest correlation. However, a prediction of result could 
not be extrapolated since the r square of all possible combination was not higher than 0.87 
(cardiac blood and brain) (Table 6).    
 
 
3.5.2 Results above 0.3mg/L for cardiac blood 
 
In order to investigate whether our data corresponded to Logan’s work 65 we also analysed data 
for morphine concentration in cardiac blood above and below 0.3mg/L. 
In the PCA plot below (Fig. 2) PC1 contains 73.7 % while PC2 contains 10.6% and PC3 
contains 6.7 % of the total variance. The situation represented in the plot was completely 
different from the previous ones, showing all matrices but vitreous grouped at the bottom of 
the plot, with bone marrow and brain overlaid, all the bloods close to each other, liver and 
muscle beside each other.  
From the Pearson correlation table below brain and cardiac blood showed again to be the two 
matrices with the highest correlation. Cardiac blood and femoral blood r square was 0.7, cardiac 
blood and preserved femoral blood was 0.8 (Table 7).   
 
3.5.3 Results below 0.3mg/L for cardiac blood 
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For cardiac blood results below 0.3 mg/L the PCA plot and the Pearson table (Fig. 3 and Table 
7) showed a complete opposite situation compare to the one described by Logan. There was 
not significant correlation between cardiac and femoral blood with r square below 0.57.  
 
3.6 Postmortem redistribution of morphine, morphine-3-glucuronide and morphine-6-
glucuronide 
 
Postmortem redistribution is the change in concentration of a drug (or chemical) at a specific 
anatomical site in the body in the time following death. This can result in the decrease, or most 
commonly increase in the concentration of a drug after death leading to complications in the 
interpretation of postmortem drug concentrations. A ratio of cardiac blood (CB) to peripheral 
(femoral) blood (FB) drug concentration >1 may indicate that a drug undergoes postmortem 
redistribution. The mean CB:FB ratio of morphine in the cases was 1.8 (range 0.1-11.0) similar 
to previous studies 1.2 (range 0.05-2.8) 66, 2.2 (range 1.0 – 5.8) 67 and 2.2 (range 0.2-9.2) 65. 
Our mean CB:FB for M3G 2.74 (range 0.0 – 8.7) and M6G mean 2.6 (range 0.5 – 8.8) were 
larger than those previously reported 1.1 and 1.3 respectively 68. Indicating that M, M3G and 
M6G may all undergo postmortem redistribution however this ratio may also however just 
represent anatomical site-to-site differences in drug concentration due to incomplete 
distribution before death 69 and more studies may be needed to confirm this.  
3.5 Conclusions 
The results of this study give 44 complete cases with morphine, M3G & M6G concentrations 
to help with the interpretation of heroin and morphine related cases. It is important to note this 
case series shows that when limited samples are available, such as in decomposition, it may 
not be possible to confirm the use of morphine/heroin with toxicological analysis and that M, 
M3G and M6G may undergo postmortem redistribution, complicating any interpretation. As 
with all toxicological interpretation should be carried out with as much information as possible. 
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      Fig 1: 3D scatterplot for morphine concentration for all biological matrices analysed 
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Fig 2: 3D scatterplot for mophine concentration with cardiac blood results higher than 0.3 mg/L 
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Fig 3: 3D scatterplot for morphine concentration with cardiac blood results below 0.3 mg/L 
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Table 1: A) Validation Data for Quantitation of Morphine in Various Matrices by Liquid Chromatography-Mass Spectrometry (LC-MS/MS)  
 
 
 Plasma Blood Liver Muscle Bone Marrow Brain Vitreous 
 
QC Concentration (mg/L) 
 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
Accuracy (%) 
 
4.4 -0.2 0.8 -3.5 4.9 -8.9 6.6 -5.0 7.4 -14.6 8.6 8.2 12.2 -4.9 
Precision (Within-run) (%CV) 
 
9.5 7.6 2.7 1.9 2.1 1.9 1.3 1.97 3.1 1.6 11.4 3.5 3.58 0.9 
Precision (Between-run) (%CV) 
 
-12.9 14.8 6.1 6.5 8.9 3.1 8.6 11.2 3.7 8.4 8.1 5.1 11.8 3.6 
Ion suppression/Enhancement (%) 
 
-7.9 -11.0 -11.3 -7.7 2.0 -10.4 -8.2 -2.4 -15.3 -12.9 -12.5 5.3 5.0 -6.1 
Recovery (%) 
 
76.3 77.7 65.0 56.4 37.9 47.8 93.1 73.8 88.1 102.6 81.1 79.1 72.2 75.1 
 
 
Table 1 B) Validation Data for Quantitation of morphine-3-glucuronide in Various Matrices by Liquid Chromatography-Mass Spectrometry (LC-
MS/MS) 
 
 
 Plasma Blood Liver Muscle Bone Marrow Brain Vitreous 
 
QC Concentration (mg/L) 
 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
Accuracy (%) 
 
1.9 0.6 6.9 7.25 14.1 14.2 -9.0 -2.3 -1.34 -7.7 5.0 6.3 9.51 14.82 
Precision (Within-run) (%CV) 
 
10.1 8.1 10.6 7.1 14.7 1.7 0.3 4.4 2.5 8.1 8.0 5.5 11.54 13.1 
Precision (Between-run) (%CV) 
 
-13.0 -10.6 11.6 9.6 12.2 11.8 7.9 9.7 12.3 11.3 13.7 5.6 9.9 7.5 
Ion suppression/Enhancement (%) 
 
19.3 -1.3 3.4 7.4 2.8 9.8 7.0 3.3 -3.5 -7.6 10.2 19.1 19.4 14.8 
Recovery (%) 
 
62.1 62.0 62.3 66.2 36.5 47.2 105.5 108.1 97.5 94.6 84.2 76.2 67.8 62.8 
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Table 1 C) Validation Data for Quantitation of morphine-6-glucuronide in Various Matrices by Liquid Chromatography-Mass Spectrometry (LC-
MS/MS) 
 
 
 Plasma Blood Liver Muscle Bone Marrow Brain Vitreous 
 
QC Concentration (mg/L) 
 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
 
0.025 
 
0.5 
Accuracy (%) 
 
6.4 6.3 10.2 12.6 12.7 -11.1 14.4 -14.5 3.1 -7.1 9.9 6.7 -9.12 13.5 
Precision (Within-run) (%CV) 
 
8.8 11.4 4.53 5.6 14.3 4.3 3.4 2.9 6.5 5.4 6.4 2.0 4.8 0.2 
Precision (Between-run) (%CV) 
 
-11.9 9.3 11.7 14.4 14.7 12.2 8.6 8.4 14.9 14.7 13.2 9.2 12.6 14.7 
Ion suppression/Enhancement (%) 
 
-9.4 -13.7 -0.5 -3.2 -17.2 -13.7 9.6 19.5 9.8 9.6 13.8 -1.9 -8.4 2.3 
Recovery (%) 
 
75.6 71.2 66.7 44.9 36.5 47.2 81.2 96.7 93.8 97.9 105.4 104.7 60.0 65.3 
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Morphine M-3-G M-6-G 6-MAM Codeine Noscapine Papaverine 
Cardiac 
Blood 
100 100 86 43 82 84 59 
Fem 
Blood 
100 100 86 52 77 82 50 
Liver 95 98 89 2 55 75 59 
Muscle 86 84 50 32 34 64 41 
Bone 
Marrow 
91 75 41 5 41 70 52 
Brain 98 84 43 43 55 68 55 
Preserved 
Femoral 
Blood 
100 98 82 61 82 84 50 
Preserved 
Vitreous 
100 95 84 100 77 91 39 
 
Table 2: Frequency of positive results for each compound (expressed as a percentage) 
among all 44 cases analysed.  
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Case Matrix Morphine M-3-G M-6-G 
1 CB 0.17 0.3 0.1 
 FB 0.1 0.32 0.11 
 L 0.28 0.29 0.15 
 M BLOQ 0.06 BLOQ 
 BM 0.08 0.14 BLOQ 
 Br 0.15 BLOQ BLOQ 
 VH 0.07 0.07 0.02 
2 CB 1.02 0.37 0.09 
 FB 0.37 0.05 0.02 
 L 2.26 1.61 0.61 
 M 0.25 BLOQ 0.05 
 BM 0.97 BLOQ 0.09 
 Br 0.75 BLOQ 0.05 
 VH 0.22 0.04 0.02 
3 CB 0.1 0.29 0.13 
 FB 0.06 0.12 0.04 
 L 0.28 0.22 0.2 
 M 0.07 0.07 0.06 
 BM 0.19 0.1 0.1 
 Br 0.14 0.08 0.06 
 VH 0.04 0.2 0.06 
4 CB 0.53 0.14 0.05 
 FB 0.22 0.03 BLOQ 
 L 0.95 1.68 0.57 
 M 0.36 BLOQ BLOQ 
 BM 0.38 BLOQ BLOQ 
 Br 0.82 BLOQ BLOQ 
 VH 0.06 BLOQ BLOQ 
5 CB 0.41 0.38 0.14 
 FB 0.25 0.09 0.03 
 L 2.55 2.09 1.76 
 M 0.48 0.08 ND 
 BM 0.5 0.14 0.09 
 Br 0.14 ND ND 
 VH 0.19 0.23 0.07 
6 CB 0.15 0.13 0.04 
 FB 0.07 0.02 BLOQ 
 L 0.48 0.4 0.19 
 M 0.27 ND ND 
 BM 0.21 ND ND 
 Br 0.12 ND ND 
 VH 0.04 0.02 BLOQ 
7 CB 1.85 0.97 0.21 
 FB 1.35 0.64 0.14 
 L 2.21 4.68 1.67 
 M 1.13 0.24 0.15 
 BM 3.23 0.32 0.07 
 Br 1.96 1.12 0.04 
 VH 0.33 0.31 0.07 
8 CB 0.3 0.71 0.15 
 FB 0.21 0.27 0.06 
 L 0.78 1.25 0.46 
 M ND ND ND 
 BM 0.31 0.07 0.06 
 Br 0.24 BLOQ 0.03 
 VH 0.11 0.12 0.04 
Case Matrix Morphine M-3-G M-6-G 
9 CB 0.49 0.89 0.28 
 FB 0.33 0.41 0.13 
 L 1.12 1.04 0.43 
 M ND 0.2 0.06 
 BM 0.24 0.19 0.06 
 Br 0.27 0.05 BLOQ 
 VH 0.18 0.46 0.1 
10 CB 0.56 0.73 0.17 
 FB 0.57 0.48 0.09 
 L 0.69 0.53 0.19 
 M 0.5 0.11 ND 
 BM 0.59 0.2 ND 
 Br 0.51 0.03 ND 
 VH 0.1 0.12 0.02 
11 CB 0.03 0.06 BLOQ 
 FB 0.13 0.13 0.04 
 L 0.98 2.01 0.11 
 M 0.13 0.23 0.09 
 BM 0.07 0.11 BLOQ 
 Br 0.06 BLOQ ND 
 VH 0.03 0.15 0.03 
12 CB 0.02 0.14 0.03 
 FB 0.03 0.11 0.02 
 L 0.08 0.09 BLOQ 
 M BLOQ BLOQ ND 
 BM BLOQ BLOQ ND 
 Br 0.07 BLOQ ND 
 VH 0.03 0.05 0.02 
13 CB 0.29 0.26 0.06 
 FB 0.08 0.14 0.04 
 L 0.21 0.25 0.15 
 M 0.12 0.13 0.08 
 BM 0.21 0.12 0.07 
 Br 0.21 0.11 0.05 
 VH 0.15 0.19 0.06 
14 CB 0.2 0.27 0.09 
 FB 0.1 0.05 0.02 
 L 0.44 0.23 0.16 
 M 0.06 BLOQ ND 
 BM 0.05 BLOQ ND 
 Br 0.18 BLOQ ND 
 VH 0.06 0.08 0.02 
15 CB BLOQ 0.01 ND 
 FB BLOQ 0.01 ND 
 L ND ND ND 
 M ND ND ND 
 BM ND ND ND 
 Br ND ND ND 
 VH BLOQ ND ND 
16 CB 0.02 0.06 0.01 
 FB 0.02 0.02 ND 
 L 0.08 BLOQ BLOQ 
 M 0.06 BLOQ ND 
 BM BLOQ BLOQ ND 
 Br 0.07 BLOQ ND 
 VH 0.06 0.05 0.01 
     
     
Case Matrix Morphine M-3-G M-6-G 
17 CB 0.13 0.24 0.07 
 FB 0.14 0.33 0.07 
 L 0.37 0.29 0.21 
 M 0.48 0.11 ND 
 BM ND ND ND 
 Br 0.11 0.04 ND 
 VH 0.07 0.09 BLOQ 
18 CB 0.66 0.06 0.05 
 FB 0.16 0.01 0.01 
 L 0.58 0.13 0.18 
 M 0.28 0.07 ND 
 BM 0.23 ND ND 
 31 
 
 Br 0.62 ND ND 
 VH 0.16 0.02 ND 
19 CB 0.26 0.43 0.1 
 FB 0.19 0.17 0.05 
 L 0.7 1.17 0.57 
 M 0.22 BLOQ ND 
 BM ND BLOQ ND 
 Br 0.25 BLOQ ND 
 VH 0.08 0.15 0.01 
20 CB 0.3 0.56 0.11 
 FB 0.33 0.38 0.07 
 L 0.73 0.17 BLOQ 
 M BLOQ 0.07 ND 
 BM BLOQ 0.06 ND 
 Br 0.27 0.05 BLOQ 
 VH 0.15 0.25 0.06 
21 CB 0.02 0.02 ND 
 FB 0.02 0.02 ND 
 L 0.08 0.1 ND 
 M BLOQ BLOQ ND 
 BM BLOQ BLOQ ND 
 Br BLOQ BLOQ ND 
 VH 0.02 0.02 ND 
22 CB 0.11 0.04 ND 
 FB 0.01 0.02 ND 
 L 0.19 0.18 0.13 
 M 0.14 BLOQ ND 
 BM 0.12 BLOQ ND 
 Br 0.08 BLOQ ND 
 VH 0.02 BLOQ ND 
23 CB 0.04 0.08 ND 
 FB 0.03 0.08 ND 
 L 0.13 0.08 ND 
 M 0.01 ND ND 
 BM 0.1 ND ND 
 Br 0.04 ND ND 
 VH 0.02 0.06 ND 
24 CB BLOQ 0.09 ND 
 FB BLOQ 0.02 ND 
 L 0.05 0.09 ND 
 M ND ND ND 
 BM 0.01 ND ND 
 Br 0.01 ND ND 
 VH BLOQ ND ND 
     
     
Case Matrix Morphine M-3-G M-6-G 
25 CB 0.78 1.14 0.48 
 FB 0.78 1.12 0.66 
 L 1.34 1.85 0.83 
 M 0.64 0.23 0.09 
 BM 0.49 0.04 ND 
 Br 0.46 0.04 ND 
 VH 0.27 0.32 0.07 
26 CB 0.33 0.24 0.12 
 FB 0.14 0.03 0.02 
 L 0.33 0.39 0.28 
 M 0.09 ND ND 
 BM 0.25 ND ND 
 Br 0.36 ND ND 
 VH 0.05 0.03 0.02 
27 CB 0.01 0.03 ND 
 FB 0.02 0.04 0.01 
 L ND BLOQ ND 
 M ND BLOQ ND 
 BM 0.12 0.01 ND 
 Br 0.04 BLOQ ND 
 VH 0.02 0.02 ND 
28 CB 0.09 0.19 0.04 
 FB 0.1 0.53 0.08 
 L 0.47 0.24 0.09 
 M 0.11 0.25 0.08 
 BM 0.11 0.17 ND 
 Br 0.28 0.08 ND 
 VH 0.12 0.65 0.08 
29 CB 0.35 0.79 0.16 
 FB 0.21 0.33 0.05 
 L 0.67 0.59 0.36 
 M 0.19 0.07 ND 
 BM 0.49 0.07 ND 
 Br 0.21 0.05 ND 
 VH 0.08 0.18 0.03 
30 CB 0.49 1.74 0.21 
 FB 0.51 0.99 0.12 
 L 1.19 1.7 0.24 
 M 0.89 0.91 BLOQ 
 BM 0.3 0.13 BLOQ 
 Br 0.5 BLOQ BLOQ 
 VH 0.19 0.33 0.03 
31 CB 0.59 1.74 0.35 
 FB 0.19 0.27 0.04 
 L 0.88 0.61 0.36 
 M 0.28 0.14 BLOQ 
 BM 0.07 BLOQ ND 
 Br 0.17 0.04 BLOQ 
 VH 0.1 0.24 0.03 
32 CB 0.29 0.57 0.09 
 FB 0.24 0.45 0.04 
 L 0.77 1.12 0.6 
 M 0.21 0.07 BLOQ 
 BM BLOQ BLOQ BLOQ 
 Br 0.2 0.4 BLOQ 
 VH 0.2 0.57 0.03 
     
     
Case Matrix Morphine M-3-G M-6-G 
33 CB 0.3 0.13 0.02 
 FB 0.3 0.16 0.02 
 L 0.77 0.94 0.54 
 M BLOQ BLOQ ND 
 BM 0.49 BLOQ BLOQ 
 Br 0.28 BLOQ ND 
 VH 0.49 0.2 0.02 
34 CB 0.85 0.9 0.29 
 FB 0.39 0.17 0.06 
 L 1.46 1.19 0.49 
 M 0.31 0.14 BLOQ 
 BM 0.05 BLOQ ND 
 Br 0.71 0.07 BLOQ 
 VH 0.33 0.62 0.19 
35 CB 0.01 0.02 BLOQ 
 FB 0.16 0.89 0.16 
 L 0.1 BLOQ BLOQ 
 M BLOQ BLOQ BLOQ 
 BM BLOQ BLOQ BLOQ 
 Br BLOQ BLOQ BLOQ 
 VH 0.03 0.02 0.01 
36 CB 0.12 0.17 0.03 
 FB 0.09 0.2 0.04 
 32 
 
 L 0.2 0.17 0.09 
 M 0.07 0.07 BLOQ 
 BM BLOQ ND ND 
 Br 0.12 BLOQ BLOQ 
 VH 0.11 0.1 0.02 
37 CB 0.08 0.27 0.03 
 FB 0.1 0.48 0.03 
 L 0.25 0.14 0.07 
 M BLOQ BLOQ BLOQ 
 BM BLOQ ND ND 
 Br 0.09 0.04 BLOQ 
 VH 0.1 0.14 0.02 
38 CB BLOQ 0.02 BLOQ 
 FB BLOQ 0.01 BLOQ 
 L BLOQ BLOQ BLOQ 
 M ND ND ND 
 BM ND ND ND 
 Br BLOQ BLOQ ND 
 VH 0.01 0.03 BLOQ 
39 CB 0.22 0.2 0.04 
 FB 0.15 0.06 0.01 
 L 0.44 0.79 0.24 
 M 0.2 BLOQ ND 
 BM BLOQ ND ND 
 Br 0.06 BLOQ ND 
 VH 0.07 0.04 BLOQ 
40 CB 0.19 0.71 0.13 
 FB 0.17 0.4 0.06 
 L 0.41 0.46 0.25 
 M 0.13 0.13 BLOQ 
 BM BLOQ BLOQ ND 
 Br 0.2 0.07 BLOQ 
 VH 0.08 0.31 0.04 
     
     
Case Matrix Morphine M-3-G M-6-G 
41 CB 0.07 0.12 0.02 
 FB 0.05 0.14 0.02 
 L 0.14 0.11 0.05 
 M BLOQ BLOQ BLOQ 
 BM BLOQ BLOQ BLOQ 
 Br 0.05 BLOQ BLOQ 
 VH 0.04 0.1 0.01 
42 CB 0.35 0.26 0.06 
 FB 0.19 0.03 BLOQ 
 L 0.9 0.81 0.23 
 M 0.09 BLOQ BLOQ 
 BM 0.3 BLOQ BLOQ 
 Br 0.21 BLOQ ND 
 VH 0.07 0.02 BLOQ 
43 CB 0.01 0.12 0.01 
 FB BLOQ 0.05 BLOQ 
 L BLOQ BLOQ BLOQ 
 M BLOQ BLOQ BLOQ 
 BM BLOQ BLOQ BLOQ 
 Br BLOQ BLOQ BLOQ 
 VH 0.03 0.05 BLOQ 
44 CB 0.27 0.03 BLOQ 
 FB 0.13 BLOQ BLOQ 
 L 0.56 0.84 0.29 
 M 0.13 BLOQ BLOQ 
 BM 0.22 BLOQ BLOQ 
 Br 0.27 BLOQ ND 
 VH 0.13 0.07 BLOQ 
 
Table 3: Concentrations of Morphine, Morphine-3-
Glucuronide and Morphine-6-Glucurionide observed in 
a variety of autopsy samples.  
 
Abbreviations: CB – Cardiac Blood, FB – Femoral Blood,             
L – Liver, M – Muscle (Psoas), BM – Bone Marrow,                    
Br – Brain (Thalamus), VH – Vitreous Humour, ND- Not 
Detected,                 BLOQ – Detected Below Limit of 
Quantitation,                               M-3-G – Morphine-3-
Glucuronide, M-6-G – Morphine-6-Glucuronide 
Concentrations: Fluids – mg/L Solids – mg/kg 
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Analyte  
Morphine 
Cardiac 
Blood 
(mg/L) 
Fem Blood 
(mg/L) 
Liver 
(mg/kg) 
Muscle 
(mg/kg) 
Bone M 
(mg/kg) 
Brain 
(mg/kg) 
F/O 
Fem 
Blood 
(mg/L) 
Vitreous 
(mg/L) 
Range 
0.01-
1.85 
0.01-1.35 
0.01-
2.55 
0.01-1.13 
0.01-
3.23 
0.01-1.96 
0.01-
1.19 
0.01-0.49 
Mean 0.30 0.20 0.65 0.21 0.26 0.26 0.18 0.11 
Median 0.21 0.14 0.48 0.13 0.12 0.18 0.14 0.08 
M3G         
Range 
0.01-
1.74 
0.01-1.12 
0.01-
4.68 
0.01-0.91 
0.01-
0.32 
0.01-1.12 
0.01-
0.88 
0.01-0.65 
Mean 0.38 0.23 0.71 0.09 0.06 0.07 0.20 0.16 
Median 0.24 0.14 0.39 0.07 0.01 0.01 0.13 0.10 
M6G         
Range 
0.01-
0.48 
0.01-0.66 
0.01-
1.76 
0.01-0.15 
0.01-
0.1 
0.01-0.06 
0.01-
0.46 
0.01-0.19 
Mean 0.10 0.06 0.33 0.03 0.03 0.02 0.06 0.03 
Median 0.08 0.04 0.21 0.01 0.01 0.01 0.04 0.02 
 
Table 4: Morphine, Mophine-3-glucuronide and Mophine-6-glucuronide range, mean and median from all cases 
analysed.  
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Table 5: Blood concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide in postmortem (PM) and driving under the influence of drugs (DUID) 
cases. 
 
Reference Case Type Sample Number of cases [Morphine] mg/L [M3G] mg/L [M6G] mg/L 
        Median Range Median Range Median Range 
This Study PM Femoral 44 0.14 0.01 - 1.19 0.14 0.01 - 1.12 0.04 0.01 - 0.66 
16 PM Femoral 45 0.22 0.01 – 1.1 0.25 0.0036 – 2.4 0.052 0.015 – 0.58  
18 PM Femoral ? 0.11 0.01 - 0.57     
 
  
50 PM Femoral 8 0.26 0 – 0.8 0.36 0 - 1.04 0.1 0 - 0.29 
70 PM Femoral 126 0.22 0.01 – 3.55     
 
  
71 PM Femoral 28 0.16 0.02 – 3.30     
 
  
68 PM Femoral 40 0.25 0.06 – 0.80 0.43 0.13 - 2.22 0.09 0.02 - 0.5 
65 PM Femoral 32 0.08 0.007 – 1.61        
6 PM Femoral 766 0.24 0.04 – 5.5        
6 DUID Blood 124 0.15 0.02 - 1.13         
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 Cardiac 
Blood 
Femoral 
Blood 
Liver Muscle 
Bone 
Marrow 
Brain 
Preserved 
Femoral Blood 
Femoral Blood 0.793       
Liver 0.632 0.511      
Muscle 0.573 0.683 0.435     
Bone Marrow 0.698 0.703 0.389 0.476    
Brain 0.872 0.737 0.440 0.553 0.765   
Preserved 
Femoral Blood 
0.844 0.917 0.485 0.579 0.739 0.788  
Preserved 
Vitreous 
0.448 0.446 0.427 0.219 0.244 0.344 0.419 
Table 6: r2 values describing correlation for data where zero was included. 
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Cardiac Blood Fem Blood Liver Muscle Bone Marrow Brain F/O Fem Blood 
correlation for data with cardiac blood results higher than 0.3 mg/L 
Fem Blood         0.706       
Liver 0.489 0.330      
Muscle 0.560 0.716 0.384     
Bone Marrow 0.728 0.712 0.335 0.490    
Brain 0.860 0.660 0.292 0.520 0.766   
F/O Fem Blood 0.805 0.918 0.324 0.632 0.785 0.760  
Vitreous 0.202 0.230 0.217 0.080 0.144 0.139 0.194 
correlation for data with cardiac blood results lower than 0.3 mg/L 
Fem Blood 0.571       
Liver 0.473 0.595      
Muscle 0.311 0.320 0.332     
Bone Marrow 0.049 0.003 0.042 0.004    
Brain 0.622 0.399 0.426 0.167 0.125   
F/O  
Fem Blood 
0.438 0.541 0.257 0.095 0.003 0.265  
Vitreous 0.552 0.540 0.342 0.152 0.008 0.571 0.518 
Table  7: r2 values describing correlation for data with cardiac blood results higher and lower than 0.3 
mg/L 
 
 
 
 
